This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
R. Walker and E. M. Nelson, Fresh and Dried Yeast as Source of Vitamin C, Am. J. Physiol. 103, 25–9 (1933).
L. Allen, K. Kimura, J. Mackichan and W. A. Ritschel, Manual of Symbols, Equations & Definitions in Pharmacokinetics (Committee for Pharmacokinetic Nomenclature of the American College of Clinical Pharmacology, Philadelphia, 1982).
L. P. Balant, L. Z. Benet, H. Blume, G. Bozler, D. D. Breimer, M. Eichelbaum, U. Gunder-Remy, J. L. Hirtz, E. Mutschler, K. K. Midha, A. G. Rauws, W. A. Ritschel, L. N. Sansom, J. P. Skelly and K. O. Vollmer, Is there a need for a more precise definition of bioavailability?, Eur. J. Clin. Pharmacol. 40, 123–6 (1991).
Bioavailability and Bioequivalence Requirements, Federal Register, Vol. 42, no. 5, pp. 1624–53; January 7, 1977.
M. Rowland and G. Tucker, Symbols in Pharmacokinetics, J. Pharmacokin. Biopharm. 8, 497–507 (1980).
CDER, Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations (U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, Maryland, October 2000).
CVM, Docket No. 94D-0401, Bioequivalence Guidance (U. S. Center for Veterinary Medicine, Food and Drug Administration, Rockville, Maryland, October 10, 2000).
Committee for Proprietary Medicinal Products, Note for Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98 (The European Agency for the Evaluation of Medicinal Products, Evaluation of Medicines for Human Use, London, 26 July 2001).
Committee for Veterinary Medicinal Products, Guidelines for the Conduct of Bioequivalence Studies for Veterinary Medicinal Products, EMEA/CVMP/016/00-corr-FINAL. (The European Agency for the Evaluation of Medicinal Products, Veterinary Medicines and Information Technology, London, 11 July 2001).
C. M. Metzler, Bioavailability — A Problem in Equivalence, Biometrics 30, 309–17 (1974)
A. Rescigno and A. Marzo, Area Under the Curve, Bioavailability, and Clearance, J. Pharmacokin. Biopharm, 19, 473–82 (1991).
A. Rescigno, Area Under the Curve and Bioavailability, Pharmacol. Res. 42, 539–40 (2000).
A. Marzo and A. Rescigno, Pharmacokinetics of endogenous substances: Some problems and some solutions, Eur. J. Drug Metab. Pharmacokin. 18, 77–88 (1993).
A. Rescigno, A. K. Thakur and A. Marzo, On Definition and Use of the Term Bioavailability, Arzneim.-Forsch. 44, 1167–9 (1994).
F. Y. Bois, T. N. Tozer, W. W. Hauck, M. L. Chen, R. Patnail and R. L. Williams, Bioequivalence: performance of several measures of extent of absorption, Pharm. Res. 11, 715–22 (1994).
R. Schall and H. G. Luus, Comparison of absorption rates in bioequivalence studies of immediate release drug fomulations, Internat. J. Clin. Pharmacol. Therapy Toxicol. 30, 153–9 (1992).
A. Rescigno, On Absorption Rate and Fraction Absorbed, J. Pharmacokin. Biopharm. 22, 255–7 (1994).
A. Rescigno, Rate of Absorption, Pharmacol. Res. 35, 5–6 (1997).
M. Farolfi, J. D. Powers and A. Rescigno, On the determination of bioequivalence, Pharmacol. Res. 37, 93–5 (1998).
F. Y. Bois, T. N. Tozer, W. W. Hauck, M. L. Chen, R. Patnail and R. L. Williams, Bioequivalence: performance of several measures of rate of absorption, Pharm. Res. 11, 966–74 (1994).
A. E. Pusateri and D. C. Kenison, Measurement of zeranol in plasma from three blood vessles in steers implanted with zeranol, J. Animal Sci. 71, 415–9 (1993).
P. Macheras and P. Argyrakis, Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity?, Pharm. Res. 14, 842–7 (1997).
Reference [6], pages 8–9.
A. Rescigno and J. D. Powers, AUC and Cmax are not sufficient to prove bioequivalence, Pharmacol. Res. 37, 93–5 (1998).
A. Rescigno, J. D. Powers and E. E. Herderick, Bioequivalent or Nonbioequivalent?, Pharmacol. Res. 43, 543–6 (2001).
T. N. Tozer, F. Y. Bois, W. W. Hauck, M. L. Chen and R. L. Williams, Absorption Rate Vs. Exposure: Which Is More Useful for Bioequivalence Testing?, Pharm. Res. 13, 453–6 (1996).
A. Rescigno, Bioequivalence, Pharm. Res. 9, 925–8 (1992).
Reference [9], page 2.
W. Schmeidler and W. Dreetz, Functional Analysis, in: Fundamentals of Mathematics, Volume III, edited by H. Behnke, F. Bachmann, K. Fladt and W. Süss (The MIT Press, Cambridge, Mass., 1974), pp. 391–445.
A. Kolmogoroff, Sulla determinazione empirica di una legge di distribuzione, Giornale dell’Istituto Italiano degli Attuari, 4, 83–91 (1933).
N. V. Smirnov, On the Estimation of the Discrepancy between Empirical Curves of Distribution for Two Independent Samples (in Russian), Bulletin of the Moscow University, 2, 3–16 (1939).
R. Bartoszynski, J. D. Powers, E. E. Herderick and J. A. Pultz, Statistical Comparison of Dissolution Curves, Pharmacol. Res. 43, 369–87 (2001).
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
(2004). Bioavailability and Bioequivalence. In: Foundations of Pharmacokinetics. Springer, Boston, MA. https://doi.org/10.1007/0-306-47924-9_17
Download citation
DOI: https://doi.org/10.1007/0-306-47924-9_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-47704-1
Online ISBN: 978-0-306-47924-3
eBook Packages: Springer Book Archive